Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-022247
Filing Date
2023-05-15
Accepted
2023-05-15 16:29:57
Documents
113
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q gls-20230331.htm   iXBRL 10-Q 3264554
2 EX-31.1 gls-ex31_1.htm EX-31.1 19426
3 EX-31.2 gls-ex31_2.htm EX-31.2 22325
4 EX-32.1 gls-ex32_1.htm EX-32.1 13911
5 EX-32.2 gls-ex32_2.htm EX-32.2 13905
  Complete submission text file 0000950170-23-022247.txt   14323944

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gls-20230331.xsd EX-101.SCH 122694
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gls-20230331_pre.xml EX-101.PRE 668890
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT gls-20230331_def.xml EX-101.DEF 475946
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT gls-20230331_cal.xml EX-101.CAL 78169
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gls-20230331_lab.xml EX-101.LAB 790069
107 EXTRACTED XBRL INSTANCE DOCUMENT gls-20230331_htm.xml XML 2894204
Mailing Address 501 BOYLSTON STREET, SUITE 6102 BOSTON MA 02116
Business Address 501 BOYLSTON STREET, SUITE 6102 BOSTON MA 02116 857-327-7737
GELESIS HOLDINGS, INC. (Filer) CIK: 0001805087 (see all company filings)

EIN.: 844730610 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39362 | Film No.: 23923063
SIC: 2834 Pharmaceutical Preparations